Live Webcast Beginning at 12 PM Eastern Time
TORONTO, Nov. 19, 2015 /CNW/ - Transition Therapeutics
Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH)
announced today that it will host an Investor Day on Monday, November 23rd in New York City. An
industry key opinion leader, Jacobo
Mintzer, MD, and Transition's executive management team will
offer insights into Transition's lead drug candidate, ELND005, and
its potential role in the treatment of severe agitation and
aggression in Alzheimer's disease.
The presentations, followed by a question-and-answer session,
will be webcast live beginning at 12 PM
Eastern Time. The webcast and accompanying
presentation materials will be accessible live and archived on the
corporate website at www.transitiontherapeutics.com.
The event will be held at the NY Palace Hotel and is open to
institutional investors, sell side analysts and investment
bankers.
About Transition
Transition is a biopharmaceutical company, developing novel
therapeutics for disease indications with large markets. The
Company's lead CNS drug candidate is ELND005 for the treatment of
Alzheimer's disease and Down syndrome. Transition's lead
metabolic drug candidate is TT-401 (LY2944876) for the treatment of
type 2 diabetes and accompanying obesity. The Company's shares are
listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock
Exchange under the symbol "TTH". For additional information about
the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases
should be considered accurate only as of the date of the release
and may be superseded by more recent information we have disclosed
in later press releases, filings with the OSC, SEC or otherwise.
Except for historical information, this press release may contain
forward-looking statements, relating to expectations, plans or
prospects for Transition, including conducting clinical trials and
potential efficacy of its products. These statements are based upon
the current expectations and beliefs of Transition's management and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
factors beyond Transition's control and the risk factors and other
cautionary statements discussed in Transition's quarterly and
annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.